CN116635022A - 用于治疗或预防冠状病毒感染和/或covid-19细胞因子风暴的mek抑制剂 - Google Patents

用于治疗或预防冠状病毒感染和/或covid-19细胞因子风暴的mek抑制剂 Download PDF

Info

Publication number
CN116635022A
CN116635022A CN202180059642.7A CN202180059642A CN116635022A CN 116635022 A CN116635022 A CN 116635022A CN 202180059642 A CN202180059642 A CN 202180059642A CN 116635022 A CN116635022 A CN 116635022A
Authority
CN
China
Prior art keywords
cov
sars
mek inhibitor
atr
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180059642.7A
Other languages
English (en)
Chinese (zh)
Inventor
S·路德维希
O·普朗兹
H·E·霍夫曼
J·科赫海尔
M·辛德勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Münster
Original Assignee
University of Münster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Münster filed Critical University of Münster
Publication of CN116635022A publication Critical patent/CN116635022A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180059642.7A 2020-05-20 2021-05-20 用于治疗或预防冠状病毒感染和/或covid-19细胞因子风暴的mek抑制剂 Pending CN116635022A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20175739.0A EP3912623B1 (en) 2020-05-20 2020-05-20 Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm
EP20175739.0 2020-05-20
PCT/EP2021/063485 WO2021234097A1 (en) 2020-05-20 2021-05-20 Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm

Publications (1)

Publication Number Publication Date
CN116635022A true CN116635022A (zh) 2023-08-22

Family

ID=70802645

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180059642.7A Pending CN116635022A (zh) 2020-05-20 2021-05-20 用于治疗或预防冠状病毒感染和/或covid-19细胞因子风暴的mek抑制剂

Country Status (11)

Country Link
US (1) US20230241014A1 (cg-RX-API-DMAC7.html)
EP (2) EP3912623B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023526836A (cg-RX-API-DMAC7.html)
KR (1) KR20230013077A (cg-RX-API-DMAC7.html)
CN (1) CN116635022A (cg-RX-API-DMAC7.html)
AU (1) AU2021277517A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022023013A2 (cg-RX-API-DMAC7.html)
CA (1) CA3178137A1 (cg-RX-API-DMAC7.html)
ES (1) ES2995196T3 (cg-RX-API-DMAC7.html)
MX (1) MX2022014561A (cg-RX-API-DMAC7.html)
WO (1) WO2021234097A1 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3697405T1 (sl) 2017-10-17 2021-11-30 Atriva Therapeutics Gmbh Novi zaviralec MEK za zdravljenje virusnih in bakterijskih okužb
LU101183B1 (en) * 2019-04-16 2020-10-16 Atriva Therapeutics Gmbh Novel mek-inhibitor for the treatment of viral and bacterial infections
CN115151533B (zh) 2020-01-10 2025-08-08 医疗免疫工程公司 Mek抑制剂及其治疗用途
WO2023084489A1 (en) * 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating coronavirus disease 2019
EP4186500A1 (en) * 2021-11-24 2023-05-31 Atriva Therapeutics GmbH Mek inhibitors for the prevention and treatment of long covid syndrome
WO2024042050A1 (en) * 2022-08-22 2024-02-29 Atriva Therapeutics Gmbh Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs
WO2024073077A1 (en) * 2022-09-30 2024-04-04 60 Degrees Pharmaceuticals Llc Methods for the treatment and prevention of diseases or infections with mcp-1 involvement by administration of tafenoquine
CN116270588B (zh) * 2022-12-26 2025-07-25 中国科学技术大学 Mek1/2抑制剂u0126在治疗car t细胞引起的crs中的应用
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN117562890B (zh) * 2023-08-03 2026-05-19 中国医学科学院医药生物技术研究所 一种色酮类化合物在制备抗冠状病毒药物中的用途
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122058A1 (en) * 2001-03-06 2004-06-24 Dorian Bevec Use of specific compounds particularly kinase inhibitors for treating viral infections
CN114007598A (zh) * 2019-04-16 2022-02-01 归属疗法有限公司 用于治疗病毒和细菌感染的新型mek抑制剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3697405T1 (sl) * 2017-10-17 2021-11-30 Atriva Therapeutics Gmbh Novi zaviralec MEK za zdravljenje virusnih in bakterijskih okužb

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122058A1 (en) * 2001-03-06 2004-06-24 Dorian Bevec Use of specific compounds particularly kinase inhibitors for treating viral infections
CN114007598A (zh) * 2019-04-16 2022-02-01 归属疗法有限公司 用于治疗病毒和细菌感染的新型mek抑制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARTIN LAURE,等: "Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model", ANTIVIRAL RESEARCH, vol. 178, 15 April 2020 (2020-04-15) *
PAOLO FAGONE,等: "Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies", AUTOIMMUNITY REVIEW, vol. 19, no. 7, 3 May 2020 (2020-05-03), XP086161717, DOI: 10.1016/j.autrev.2020.102571 *

Also Published As

Publication number Publication date
EP3912623A1 (en) 2021-11-24
AU2021277517A1 (en) 2022-12-08
EP3912623B1 (en) 2024-07-31
CA3178137A1 (en) 2021-11-25
JP2023526836A (ja) 2023-06-23
EP4153159A1 (en) 2023-03-29
EP3912623C0 (en) 2024-07-31
KR20230013077A (ko) 2023-01-26
ES2995196T3 (en) 2025-02-07
MX2022014561A (es) 2022-12-15
WO2021234097A1 (en) 2021-11-25
BR112022023013A2 (pt) 2022-12-20
US20230241014A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
US20230241014A1 (en) Mek-inhibitors for the treatment or prevention of coronavirus infections and/or covid-19 cytokine storm
Cao et al. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence
EP4146192A1 (en) Methods and compositions for the treatment of sars-cov-2
WO2015157223A1 (en) Methods of treating coronavirus infection
Wang et al. A77 1726, the active metabolite of the anti‐rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases
US20250250548A1 (en) Methods and compositions for treating negative-sense single-stranded rna virus
Hong et al. Remdesivir as a broad-spectrum antiviral drug against COVID-19.
Du et al. Alisol B 23-acetate broadly inhibits coronavirus through blocking virus entry and suppresses proinflammatory T cells responses for the treatment of COVID-19
CN105267948B (zh) 肝细胞生长因子调节的酪氨酸激酶底物在制备防治肠道病毒71型感染药物中的应用
EP4186500A1 (en) Mek inhibitors for the prevention and treatment of long covid syndrome
US20230404988A1 (en) Prostaglandin receptor agonists for use in the treatment of a coronavirus infection such as covid-19
Bag et al. A systematic review of the efficacy and safety of favipiravir (Avigan) for the treatment of novel COVID-19 infections
EA051538B1 (ru) Ингибиторы mek для лечения или предупреждения коронавирусных инфекций и/или цитокинового шторма при covid-19
Belouzard et al. Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
US11471448B2 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
Kandler Coronavirus infections in monocytes and macrophages
Bamunuarachchi et al. Molnupiravir inhibits Bourbon virus infection and disease-associated pathology in mice
Labach In Vitro and In Vivo Characterization of the Metallodrug BOLD-100 as an Inhibitor of SARS-CoV-2 Replication
이다해 A study on effective antiviral activity of Alloferon and Zanamivir against influenza A virus (H1N1) infection
CN118178396A (zh) 霉酚酸在制备抑制汉滩病毒复制的药物中的应用
WO2024042050A1 (en) Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs
WO2022195296A1 (en) Anti viral therapy
CN121868284A (zh) 用于防治新型冠状病毒感染的药物组合物
US20180369302A1 (en) Epizootic hemorrhagic disease virus - tel aviv university (ehdv-tau) - oncolytic virus for treating cancer
BR102021006986A2 (pt) Uso de nitazoxanida para a preparação de medicamento para a prevenção ou o tratamento de infecção causada por coronavírus sars-cov-2

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination